Vanoxerine Kills Mycobacteria Through Membrane Depolarization and Efflux Inhibition

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2023 Feb 13

PMID 36778873

Authors

Alexander D H Kingdon

Asti-Rochelle Meosa-John

Sarah M Batt

Gurdyal S Besra

Affiliations

Soon will be listed here.

Abstract

is a deadly pathogen, currently the leading cause of death worldwide from a single infectious agent through tuberculosis infections. If the End TB 2030 strategy is to be achieved, additional drugs need to be identified and made available to supplement the current treatment regimen. In addition, drug resistance is a growing issue, leading to significantly lower treatment success rates, necessitating further drug development. Vanoxerine (GBR12909), a dopamine re-uptake inhibitor, was recently identified as having anti-mycobacterial activity during a drug repurposing screening effort. However, its effects on mycobacteria were not well characterized. Herein, we report vanoxerine as a disruptor of the membrane electric potential, inhibiting mycobacterial efflux and growth. Vanoxerine had an undetectable level of resistance, highlighting the lack of a protein target. This study suggests a mechanism of action for vanoxerine, which will allow for its continued development or use as a tool compound.

Citing Articles

Exploration of vanoxerine analogues as antibacterial agents.

Kingdon A, Adcock H, Kasimati E, Craven P, van Schaik W, Cox L J Antibiot (Tokyo). 2024; 78(1):54-63.

PMID: 39402358 PMC: 11700842. DOI: 10.1038/s41429-024-00781-9.

small molecule screening to inform novel candidates for use in fluconazole combination therapy against .

Mead H, Valentine M, Yin H, Thompson Iii G, Keim P, Engelthaler D Microbiol Spectr. 2024; 12(10):e0100824.

PMID: 39162534 PMC: 11448266. DOI: 10.1128/spectrum.01008-24.

Mechanisms of Triton X-100 reducing the Ag-resistance of Enterococcus faecalis.

Lv S, Duan M, Fan B, Fan W World J Microbiol Biotechnol. 2024; 40(7):231.

PMID: 38833075 DOI: 10.1007/s11274-024-04020-z.

References

Jeon A, Ackart D, Li W, Jackson M, Melander R, Melander C . 2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain. Sci Rep. 2019; 9(1):1513. PMC: 6365497. DOI: 10.1038/s41598-018-38064-7. View

Odds F . Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003; 52(1):1. DOI: 10.1093/jac/dkg301. View

Kanvatirth P, Jeeves R, Bacon J, Besra G, Alderwick L . Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria. PLoS One. 2019; 14(3):e0213713. PMC: 6414029. DOI: 10.1371/journal.pone.0213713. View

Gupta S, Cohen K, Winglee K, Maiga M, Diarra B, Bishai W . Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013; 58(1):574-6. PMC: 3910722. DOI: 10.1128/AAC.01462-13. View

Novo D, Perlmutter N, Hunt R, Shapiro H . Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry. 1999; 35(1):55-63. DOI: 10.1002/(sici)1097-0320(19990101)35:1<55::aid-cyto8>3.0.co;2-2. View

Obejero-Paz C, Bruening-Wright A, Kramer J, Hawryluk P, Tatalovic M, Dittrich H . Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk. Sci Rep. 2015; 5:17623. PMC: 4663487. DOI: 10.1038/srep17623. View

Johnson E, Office E, Kawate T, Orzechowski M, Hung D . Large-Scale Chemical-Genetic Strategy Enables the Design of Antimicrobial Combination Chemotherapy in . ACS Infect Dis. 2019; 6(1):56-63. PMC: 6958538. DOI: 10.1021/acsinfecdis.9b00373. View

Feng X, Zhu W, Schurig-Briccio L, Lindert S, Shoen C, Hitchings R . Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A. 2015; 112(51):E7073-82. PMC: 4697371. DOI: 10.1073/pnas.1521988112. View

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T . Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2012; 41(6):1393-400. PMC: 3669462. DOI: 10.1183/09031936.00125812. View

10.

Cakulev I, Lacerda A, Khrestian C, Ryu K, Brown A, Waldo A . Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. J Cardiovasc Electrophysiol. 2011; 22(11):1266-73. PMC: 3172341. DOI: 10.1111/j.1540-8167.2011.02098.x. View

11.

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L . Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014; 9(7):e102135. PMC: 4092087. DOI: 10.1371/journal.pone.0102135. View

12.

Boshoff H, Myers T, Copp B, McNeil M, Wilson M, Barry 3rd C . The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem. 2004; 279(38):40174-84. DOI: 10.1074/jbc.M406796200. View

13.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

14.

Chen C, Gardete S, Jansen R, Shetty A, Dick T, Rhee K . Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018; 62(5). PMC: 5923092. DOI: 10.1128/AAC.02107-17. View

15.

Lewis D, Matecka D, Zhang Y, Hsin L, Dersch C, Stafford D . Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents. J Med Chem. 1999; 42(24):5029-42. DOI: 10.1021/jm990291q. View

16.

Chawla M, Parikh P, Saxena A, Munshi M, Mehta M, Mai D . Mycobacterium tuberculosis WhiB4 regulates oxidative stress response to modulate survival and dissemination in vivo. Mol Microbiol. 2012; 85(6):1148-65. PMC: 3438311. DOI: 10.1111/j.1365-2958.2012.08165.x. View

17.

Su C, Klenotic P, Bolla J, Purdy G, Robinson C, Yu E . MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine. Proc Natl Acad Sci U S A. 2019; 116(23):11241-11246. PMC: 6561238. DOI: 10.1073/pnas.1901346116. View

18.

Conradie F, Diacon A, Ngubane N, Howell P, Everitt D, Crook A . Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020; 382(10):893-902. PMC: 6955640. DOI: 10.1056/NEJMoa1901814. View

19.

Remm S, Earp J, Dick T, Dartois V, Seeger M . Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev. 2021; 46(1). PMC: 8829022. DOI: 10.1093/femsre/fuab050. View

20.

Preti A . Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2001; 1(2):241-51. View